SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read Moreby Selina McKee | Apr 10, 2018 | News | 0
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read Moreby Selina McKee | Feb 21, 2018 | News | 0
Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
Read Moreby Selina McKee | Oct 10, 2017 | News | 0
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read Moreby Selina McKee | Jul 19, 2017 | News | 0
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Read Moreby Selina McKee | Jan 26, 2017 | News | 0
The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.
Read Moreby Selina McKee | Sep 26, 2016 | News | 0
The National Institute for Health and Care Excellence is endorsing Gilead’s pan-genotypic hepatitis C drug Epclusa for routine NHS use in England and Wales.
Read Moreby Selina McKee | Jun 29, 2016 | News | 0
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
